The development of STING agonists for cancer has been beset by safety issues and discontinued programmes, but Daiichi Sankyo is hoping a new antibody-drug conjugate (ADC) could succeed where others ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...

As a soldier fighting in Iraq, Brian Ericksen thought the idea of martial arts in a war zone was ridiculous. Then, one day, it clicked for him. The owner of Heaven and Earth Aikido used the calming ...

Investing.com -- Japanese pharmaceutical company Daiichi Sankyo plans to invest approximately 300 billion yen ($1.9 billion) to establish production facilities for targeted cancer medicines across ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Determining whether Sankyo Seiko Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Get the annual and quarterly balance sheet of Daiichi Sankyo Company, Limited (DSNKY) including details of assets, liabilities and shareholders' equity.

With an investment of approximately 1.1 billion yuan ($154 million), Daiichi Sankyo China broke ground on a new facility to produce antibody-drug conjugates (ADC) — an emerging class of highly potent ...